Since 11a activated COUP-TFII in the DR2 luciferase assay (Figure 1B) and induced RARB2 and NGFI-A gene expression to a comparable level as atRA (Figure S3), it is possible that 11a could serve as an agonist for COUP-TFII and substitute atRA in some cancer treatment. Here, EGR1 is linked to cancer.